✨ Free AI Report
Phathom Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Phathom Pharmaceuticals, Inc.
Company Research

Phathom Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Phathom Pharmaceuticals, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Emerging commercial-stage biopharmaceutical with established market presence in GI indications, growing revenue trajectory, and multi-indication pipeline expansion. Phathom demonstrates strong commercial traction with $175M TTM revenue (as of Dec 2025) and over 790,000 VOQUEZNA prescriptions filled, reflecting successful market penetration. The company shows solid analyst support with a 'Strong.

What is Phathom Pharmaceuticals, Inc.'s industry? Phathom Pharmaceuticals, Inc. (phathompharma.com) operates in Biopharmaceuticals - Gastrointestinal Therapeutics. AskCyborg classifies Phathom Pharmaceuticals, Inc. under Biopharmaceuticals - Gastrointestinal Therapeutics in its company registry.

Phathom Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. The company markets VOQUEZNA® (vonoprazan) for treat...

7/ 10Strong

Cyborg Score thesis

Emerging commercial-stage biopharmaceutical with established market presence in GI indications, growing revenue trajectory, and...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Gastrointestinal Therapeutics
2 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Phathom Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Phathom Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Phathom Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Phathom Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Phathom Pharmaceuticals, Inc. Overview

Pro stress-test →

Phathom Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. The company markets VOQUEZNA® (vonoprazan) for treating heartburn associated with Non-Erosive GERD, erosive GERD, and H. pylori infection, with triple and dual combination packs available for infection treatment.

Strategic Profile

Pro stress-test →

Phathom's lead asset is vonoprazan, an oral small-molecule potassium competitive acid blocker that shows rapid, potent anti-secretory effects and has demonstrated clinical benefits in treating gastroesophageal reflux disease and H. pylori infection. The company's product aims to elevate stomach pH more effectively than PPI therapies, positioning itself for adoption among physicians serving an estimated 65 million patient market.

Competitive Landscape

Pro stress-test →

Phathom competes in the GI therapeutics market against established PPI manufacturers and emerging PCAB developers. Crinetics Pharmaceuticals is noted as one of 34 identified competitors. Phathom's differentiation lies in vonoprazan's first-in-class PCAB mechanism and its superior acid elevation profile compared to traditional PPIs, establishing positioning as an innovative alternative in a large, well-defined market.

Industry Context

Phathom Pharmaceuticals, Inc. operates in Biopharmaceuticals - Gastrointestinal Therapeutics.

Key facts

Founded: 2018 · Headquarters: Florham Park, New Jersey, US · Revenue: $175M (TTM as of Dec 2025) · Market cap: $990M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Phathom Pharmaceuticals, Inc..

  • 2024 revenue reached $55.25 million, representing an 8001% increase from 2023, demonstrating explosive early commercial growth.
  • The company is advancing development programs across multiple acid-related GI disorders, including As Needed dosing for Non-Erosive GERD and Eosinophilic Esophagitis.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Jan 2026Public equity offering of 6.875 million shares completed at $16.00 per share
  • Dec 2025Q3 2025 earnings reported with net revenues of $49.5 million, up 25% quarter-over-quarter
  • +2 moreTrack every material event for Phathom Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Phathom Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Proton Pump Inhibitors (PPIs)Traditional acid-suppression therapy for GERD and related conditions→Vonoprazan competitorsPotassium-competitive acid blocker development-stage competitors→

Compare Phathom Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Phathom Pharmaceuticals, Inc. operates in Biopharmaceuticals - Gastrointestinal Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Gastrointestinal Therapeutics research →
NEW · MCP server

Ask your AI assistant about Phathom Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Phathom Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Phathom Pharmaceuticals, Inc. do this quarter?”
“Is Phathom Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Phathom Pharmaceuticals, Inc. do?+
Phathom Pharmaceuticals is a biopharmaceutical company that focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. The company markets VOQUEZNA® (vonoprazan) for treat...
What is Phathom Pharmaceuticals, Inc.'s Cyborg Score?+
Phathom Pharmaceuticals, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Phathom Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Proton Pump Inhibitors (PPIs), Vonoprazan competitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Phathom Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Phathom Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Phathom Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.